Companion Diagnostics for Cancer and Autoimmune Drugs

Sengenics has an extensive track record of working with academic and pharmaceutical collaborators to discover novel autoantibody signatures for autoimmune disease and cancer immunotherapy drugs. These signatures usually consist of a relatively low number of biomarkers that have high sensitivity and specificity, making the results highly amenable to be converted into a low-cost companion diagnostic.

Key benefits and uses

identify patients who are most likely to benefit from a particular drug;
identify patients who are more likely to be at increased risk for developing serious ADRs;
monitor response to drugs in order to adjust dosage or treatment regimes to achieve improved safety and/or efficacy.